⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 27, 2005New England Journal of Medicine

Platelet-Derived Growth Factor CC — A Clinically Useful Angiogenic Factor at Last?

Stefanie Dimmeler

View at Publisher

Ask AI

Bookmark

Share

Abstract

A member of the platelet-derived growth factor family (PDGF-CC) is necessary and sufficient to induce neovascularization in two models of ischemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stefanie Dimmeler (2005) studied this question.

synapsesocial.com/papers/6a9a18fe6bb205df309e4b0f https://doi.org/10.1056/nejmcibr050670

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitorsOriginal Research · 2004 · 172 citations
2Expanding the Evidence and Indications for Thrombectomy in Ischemic StrokeNew England Journal of Medicine · Fri,
3Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic StrokeNew England Journal of Medicine · Fri,
4Trial of Endovascular Therapy for Mild Stroke with Large-Vessel OcclusionNew England Journal of Medicine · Fri,
5Interim Analysis of a Phase 3 Trial of Povetacicept in IgA NephropathyNew England Journal of Medicine · Fri,

More from New England Journal of Medicine

Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 TrialFri,
Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy AnalysisThu,
Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial AnalysisThu,
Examining the Use of Race in Clinical AlgorithmsWed,
Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left EyeWed,